Recently Ascletis a China-based biotechnology company focused on innovative drug development, received a US$20m investment from Goldman Sachs. Up to today, Ascletis has completed two rounds of financing within the past two months. The first round US$35,000 was led by C-Bridge Capital, Tasly Pharmaceutical and Pavilion Capital.
In an interview with Jianjiong Wang, Associate Director, Ascletis Pharmaceuticals Co., Ltd.
, Wang discusses the recent investment of US$20m from Goldman Sachs and the future of Ascletis.
The Biotechnician-What specific R&D is Asceletis going to focus on now with the new investment?
The Biotechnician-Will the new investment allow your firm to be able to push more treatments through the pipeline?
Wang-Yes, we will broaden our pipeline with the new investment, furthermore, we can to use the funds to strengthen our R&D capacity, and broaden the scope of its R&D pipeline.
The Biotechnician-Will you be seeking for more funding in the next year, if so, why?
Wang-Wu-Not decided yet.
The Biotechnician-What are some of your major plans you have for 2016?
Wang-Finish all phases clinical trials for ASC08 by the end of 2016 or the beginning of 2017. Start the clinical trial for ASC16 and to complete the construction of our GMP manufacturing facilities.